Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Ann Hematol

Retrieve available abstracts of 182 articles:
HTML format
Text format



Single Articles


    March 2018
  1. HIDALGO LOPEZ JE, Carballo-Zarate A, Verstovsek S, Wang SA, et al
    Bone marrow findings in blast phase of polycythemia vera.
    Ann Hematol. 2018;97:425-434.
    PubMed     Text format     Abstract available


    February 2018
  2. ZHAO HY, Song Y, Cao XN, Qin YZ, et al
    Leukemia-propagating cells demonstrate distinctive gene expression profiles compared with other cell fractions from patients with de novo Philadelphia chromosome-positive ALL.
    Ann Hematol. 2018 Feb 10. pii: 10.1007/s00277-018-3253.
    PubMed     Text format     Abstract available


  3. NAKAYAMA S, Matsuda M, Adachi T, Sueda S, et al
    Adult T cell leukemia/lymphoma with different pathological features in each tumor site.
    Ann Hematol. 2018 Feb 9. pii: 10.1007/s00277-018-3272.
    PubMed     Text format    


  4. SUZUKI Y, Koya J, Ebisawa K, Abe H, et al
    Sequential development of monoclonal B cell lymphocytosis-derived small lymphocytic lymphoma and plasma cell leukemia.
    Ann Hematol. 2018 Feb 7. pii: 10.1007/s00277-018-3248.
    PubMed     Text format    


  5. WEI G, Hu Y, Pu C, Yu J, et al
    CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study.
    Ann Hematol. 2018 Feb 7. pii: 10.1007/s00277-018-3246.
    PubMed     Text format     Abstract available


  6. DI BLASI R, Cattaneo C, Lewis RE, Tumbarello M, et al
    Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL).
    Ann Hematol. 2018 Feb 7. pii: 10.1007/s00277-018-3252.
    PubMed     Text format     Abstract available


  7. TACHIKI L, Dong ZM, Burwick N
    Atypical chronic lymphocytic leukemia presenting with massive IgM paraprotein.
    Ann Hematol. 2018 Feb 6. pii: 10.1007/s00277-018-3261.
    PubMed     Text format    


  8. MORITA K, Koya J, Toya T, Nakamura F, et al
    Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review.
    Ann Hematol. 2018 Feb 6. pii: 10.1007/s00277-018-3263.
    PubMed     Text format    


  9. FUJIMI A, Nagamachi Y, Yamauchi N
    Extramedullary involvement of the stomach presenting as multiple white elevations in the initial diagnosis of chronic myeloid leukemia treated with dasatinib.
    Ann Hematol. 2018 Feb 6. pii: 10.1007/s00277-018-3268.
    PubMed     Text format    


  10. MARTINEZ-CUADRON D, Boluda B, Martinez P, Bergua J, et al
    A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
    Ann Hematol. 2018 Feb 2. pii: 10.1007/s00277-018-3229.
    PubMed     Text format     Abstract available


  11. MELLINGHOFF SC, Panse J, Alakel N, Behre G, et al
    Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    Ann Hematol. 2018;97:197-207.
    PubMed     Text format     Abstract available


  12. DUONG VH, Padron E, Al Ali NH, Lancet JE, et al
    The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
    Ann Hematol. 2018;97:247-254.
    PubMed     Text format     Abstract available


  13. SCHROEDER T, Rautenberg C, Kruger W, Platzbecker U, et al
    Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Ann Hematol. 2018;97:335-342.
    PubMed     Text format     Abstract available


  14. MINODA S, Akasaka T, Okanoue Y, Honjo G, et al
    Relapse of acute promyelocytic leukemia in the external auditory canal confirmed by PML/RARA dual-fusion and RARA break-apart fluorescence in situ hybridization.
    Ann Hematol. 2018 Feb 1. pii: 10.1007/s00277-018-3235.
    PubMed     Text format    


  15. SHAHKARAMI S, Mehrasa R, Younesian S, Yaghmaie M, et al
    Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
    Ann Hematol. 2018 Feb 1. pii: 10.1007/s00277-018-3230.
    PubMed     Text format     Abstract available


    January 2018
  16. SAEED OAM, Longe HO, Zhou J
    T cell large granular lymphocytic leukemia, a rare form of post lung transplant lymphoproliferative disorder.
    Ann Hematol. 2018 Jan 8. pii: 10.1007/s00277-017-3213.
    PubMed     Text format    


  17. BEN LAKHAL R, Ghedira H, Bellaaj H, Ben Youssef Y, et al
    Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ann Hematol. 2018 Jan 6. pii: 10.1007/s00277-017-3224.
    PubMed     Text format     Abstract available


  18. KAMEDA K, Kako S, Hayakawa J, Akahoshi Y, et al
    Safety of avoiding systemic corticosteroid administration for grade II acute graft-versus-host disease limited to the skin.
    Ann Hematol. 2018;97:169-179.
    PubMed     Text format     Abstract available


    December 2017
  19. ZHAO H, Zhao Y, Zhang Y, Hou J, et al
    Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia.
    Ann Hematol. 2017 Dec 30. pii: 10.1007/s00277-017-3216.
    PubMed     Text format     Abstract available


  20. SADEGHI N, Li HC
    MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab.
    Ann Hematol. 2017 Dec 28. pii: 10.1007/s00277-017-3219.
    PubMed     Text format    


  21. YANG J, Cai Y, Jiang J, Wan L, et al
    Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia.
    Ann Hematol. 2017 Dec 18. pii: 10.1007/s00277-017-3204.
    PubMed     Text format     Abstract available


  22. HARADA K, Doki N, Hagino T, Miyawaki S, et al
    Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201.
    Ann Hematol. 2017 Dec 2. pii: 10.1007/s00277-017-3156.
    PubMed     Text format     Abstract available


    November 2017
  23. HILMI M, Bally C, Burns R, Lorillon G, et al
    Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine.
    Ann Hematol. 2017 Nov 23. pii: 10.1007/s00277-017-3190.
    PubMed     Text format    


  24. HASSANI S, Khaleghian A, Ahmadian S, Alizadeh S, et al
    Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4).
    Ann Hematol. 2017 Nov 20. doi: 10.1007/s00277-017-3163.
    PubMed     Text format     Abstract available


  25. PRATS-MARTIN C, Jimenez-Guerrero P, Morales-Camacho RM, Caballero-Velazquez T, et al
    KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2017 Nov 18. doi: 10.1007/s00277-017-3187.
    PubMed     Text format    


  26. SHAO H, Yang Q, Zhang P, Liu H, et al
    Simultaneous occurrence of two distinct leukemic clones with PML-RARalpha and RUNX1-RUNX1T1 in a case of acute myeloid leukemia.
    Ann Hematol. 2017 Nov 9. doi: 10.1007/s00277-017-3169.
    PubMed     Text format    


  27. LORENZANA N, Avila LF, Alonso S, Colado E, et al
    The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment.
    Ann Hematol. 2017;96:1833-1840.
    PubMed     Text format     Abstract available


    October 2017
  28. NASSEREDDINE S, Lap CJ, Haroun F, Tabbara I, et al
    The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
    Ann Hematol. 2017 Oct 31. doi: 10.1007/s00277-017-3161.
    PubMed     Text format     Abstract available


  29. NAGEL G, Weber D, Fromm E, Erhardt S, et al
    Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).
    Ann Hematol. 2017 Oct 31. doi: 10.1007/s00277-017-3150.
    PubMed     Text format     Abstract available


  30. YANG D, Zhang X, Zhang X, Xu Y, et al
    The progress and current status of immunotherapy in acute myeloid leukemia.
    Ann Hematol. 2017 Oct 28. doi: 10.1007/s00277-017-3148.
    PubMed     Text format     Abstract available


  31. ZHANG X, Li B, Yu J, Dahlstrom J, et al
    MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
    Ann Hematol. 2017 Oct 27. doi: 10.1007/s00277-017-3158.
    PubMed     Text format     Abstract available


  32. KHAN M, Siddiqi R, Thompson PA
    Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.
    Ann Hematol. 2017 Oct 23. doi: 10.1007/s00277-017-3149.
    PubMed     Text format     Abstract available


  33. GUTIERREZ-AGUIRRE CH, Flores-Jimenez JA, Alatorre-Ricardo J, Cantu-Rodriguez OG, et al
    The prognostic significance of serum XCL1 concentration in patients with acute lymphoblastic leukemia: a pilot study.
    Ann Hematol. 2017 Oct 13. doi: 10.1007/s00277-017-3142.
    PubMed     Text format     Abstract available


  34. TERADA K, Yamaguchi H, Ueki T, Usuki K, et al
    Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor.
    Ann Hematol. 2017 Oct 4. doi: 10.1007/s00277-017-3143.
    PubMed     Text format     Abstract available


  35. IURLO A, Galimberti S, Abruzzese E, Annunziata M, et al
    Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
    Ann Hematol. 2017 Oct 2. doi: 10.1007/s00277-017-3144.
    PubMed     Text format     Abstract available


  36. YANAGIHARA T, Ikematsu Y, Kato K, Yonekawa A, et al
    Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma.
    Ann Hematol. 2017 Oct 2. doi: 10.1007/s00277-017-3146.
    PubMed     Text format    


  37. SAMADI O, Breunis H, Sandoval J, Akilan K, et al
    Return to work and work-related disability among AML survivors.
    Ann Hematol. 2017;96:1625-1633.
    PubMed     Text format     Abstract available


  38. HANSSON L, Asklid A, Diels J, Eketorp-Sylvan S, et al
    Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia.
    Ann Hematol. 2017;96:1681-1691.
    PubMed     Text format     Abstract available


  39. HAMADOU WS, Mani R, Besbes S, Bourdon V, et al
    GATA2 gene analysis in several forms of hematological malignancies including familial aggregations.
    Ann Hematol. 2017;96:1635-1639.
    PubMed     Text format     Abstract available


    September 2017
  40. HOU J, Wang S, Zhang Y, Fan D, et al
    Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
    Ann Hematol. 2017 Sep 22. doi: 10.1007/s00277-017-3130.
    PubMed     Text format     Abstract available


  41. JAWHAR M, Naumann N, Schwaab J, Baurmann H, et al
    Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
    Ann Hematol. 2017;96:1463-1470.
    PubMed     Text format     Abstract available


  42. HAROUN F, Solola SA, Nassereddine S, Tabbara I, et al
    PD-1 signaling and inhibition in AML and MDS.
    Ann Hematol. 2017;96:1441-1448.
    PubMed     Text format     Abstract available


    August 2017
  43. SHAO H, Yang Q, Wu C, Cen J, et al
    Therapy-related acute myeloid leukemia with inv(16) after successful therapy for de novo acute myeloid leukemia with t(8;21).
    Ann Hematol. 2017 Aug 24. doi: 10.1007/s00277-017-3110.
    PubMed     Text format    


  44. OH SB, Park SW, Chung JS, Lee WS, et al
    Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.
    Ann Hematol. 2017 Aug 21. doi: 10.1007/s00277-017-3104.
    PubMed     Text format     Abstract available


  45. IURLO A, Bucelli C, Cattaneo D, Orofino N, et al
    Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia.
    Ann Hematol. 2017 Aug 19. doi: 10.1007/s00277-017-3105.
    PubMed     Text format    


  46. LOU Y, Ma Y, Sun J, Suo S, et al
    Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia.
    Ann Hematol. 2017 Aug 19. doi: 10.1007/s00277-017-3096.
    PubMed     Text format     Abstract available


  47. ZHAO Y, Wang J, Luo Y, Shi J, et al
    Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
    Ann Hematol. 2017;96:1353-1360.
    PubMed     Text format     Abstract available


  48. SAGLIO G, le Coutre P, Cortes J, Mayer J, et al
    Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
    Ann Hematol. 2017;96:1303-1313.
    PubMed     Text format     Abstract available


  49. EREN R, Dogu MH, Emir S, Huq GE, et al
    Rethinking the usefulness of bone marrow biopsy on treatment decision in CLL patients at diagnosis.
    Ann Hematol. 2017;96:1315-1321.
    PubMed     Text format     Abstract available


    July 2017
  50. YUI S, Kurosawa S, Yamaguchi H, Kanamori H, et al
    D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
    Ann Hematol. 2017 Jul 31. doi: 10.1007/s00277-017-3074.
    PubMed     Text format     Abstract available


  51. NISCOLA P, Tendas A, Abruzzese E, Caravita T, et al
    Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice.
    Ann Hematol. 2017 Jul 12. doi: 10.1007/s00277-017-3064.
    PubMed     Text format    


  52. THOMAY K, Fedder C, Hofmann W, Kreipe H, et al
    Telomere shortening, TP53 mutations and deletions in chronic lymphocytic leukemia result in increased chromosomal instability and breakpoint clustering in heterochromatic regions.
    Ann Hematol. 2017 Jul 9. doi: 10.1007/s00277-017-3055.
    PubMed     Text format     Abstract available


  53. VENTURA FERREIRA MS, Crysandt M, Ziegler P, Hummel S, et al
    Evidence for a pre-existing telomere deficit in non-clonal hematopoietic stem cells in patients with acute myeloid leukemia.
    Ann Hematol. 2017 Jul 3. doi: 10.1007/s00277-017-3049.
    PubMed     Text format     Abstract available


  54. RODRIGUEZ-VEIGA R, Igual B, Montesinos P, Tormo M, et al
    Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin.
    Ann Hematol. 2017;96:1077-1084.
    PubMed     Text format     Abstract available


  55. KAUR V, Swami A
    Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
    Ann Hematol. 2017;96:1175-1184.
    PubMed     Text format     Abstract available


    June 2017
  56. URESHINO H, Kamachi K, Miyahara M
    Detection of human T-cell lymphotropic virus type I-specific cytotoxic T-cells may predict treatment responses in adult T-cell leukemia/lymphoma patients.
    Ann Hematol. 2017 Jun 27. doi: 10.1007/s00277-017-3052.
    PubMed     Text format    


  57. BALDUCCI E, Nivaggioni V, Boudjarane J, Bouriche L, et al
    Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy.
    Ann Hematol. 2017 Jun 20. doi: 10.1007/s00277-017-3050.
    PubMed     Text format    


  58. HEUSER M, Gabdoulline R, Loffeld P, Dobbernack V, et al
    Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2017 Jun 13. doi: 10.1007/s00277-017-3027.
    PubMed     Text format     Abstract available


  59. JONSSON S, Olsson B, Soderberg J, Wadenvik H, et al
    Erratum to: Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study.
    Ann Hematol. 2017 Jun 9. doi: 10.1007/s00277-017-3024.
    PubMed     Text format    


  60. DE LACERDA MP, Guedes NR, Yamakawa PE, Pereira AD, et al
    Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with (del17p).
    Ann Hematol. 2017 Jun 9. doi: 10.1007/s00277-017-3039.
    PubMed     Text format    


  61. ABLA O, Ribeiro RC, Testi AM, Montesinos P, et al
    Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.
    Ann Hematol. 2017 Jun 8. doi: 10.1007/s00277-017-3042.
    PubMed     Text format     Abstract available


  62. MUKHERJEE S, Ibrahimi S, John S, Adnan MM, et al
    Non-seminomatous mediastinal germ cell tumor and acute megakaryoblastic leukemia.
    Ann Hematol. 2017 Jun 3. doi: 10.1007/s00277-017-3037.
    PubMed     Text format     Abstract available


  63. OKA S, Ono K, Nohgawa M
    Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.
    Ann Hematol. 2017 Jun 2. doi: 10.1007/s00277-017-3032.
    PubMed     Text format    


  64. BRAULKE F, Schulz X, Germing U, Schuler E, et al
    Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
    Ann Hematol. 2017;96:887-894.
    PubMed     Text format     Abstract available


  65. CHOI DC, Tremblay D, Iancu-Rubin C, Mascarenhas J, et al
    Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.
    Ann Hematol. 2017;96:919-927.
    PubMed     Text format     Abstract available


    May 2017
  66. GONG Z, Zheng L, Tang Z, Chen Z, et al
    Erratum to: Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Ann Hematol. 2017 May 20. doi: 10.1007/s00277-017-3025.
    PubMed     Text format    


  67. HAEN SP, Groh C, Schumm M, Backert L, et al
    Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.
    Ann Hematol. 2017;96:817-827.
    PubMed     Text format     Abstract available


    April 2017
  68. MATERN S, Schmidt E, Hartmann D, Schliemann C, et al
    Successful second allogeneic stem cell transplantation in a patient with T-lymphoblastic leukemia (T-ALL) relapsed as myeloid sarcoma.
    Ann Hematol. 2017 Apr 27. doi: 10.1007/s00277-017-3000.
    PubMed     Text format    


  69. SANCHEZ R, Ayala R, Alonso RA, Martinez MP, et al
    Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.
    Ann Hematol. 2017 Apr 27. doi: 10.1007/s00277-017-3002.
    PubMed     Text format     Abstract available


  70. KOYA J, Ibaraki T, Yamazaki I, Nakamura F, et al
    Acute basophilic leukemia with add(3)(q12) accompanied by histamine excess symptoms.
    Ann Hematol. 2017 Apr 19. doi: 10.1007/s00277-017-2987.
    PubMed     Text format    


  71. ESPINOSA LARA P, Quiros Redondo V, Aguado Lobo M, Jimenez-Reyes J, et al
    Purpuric exanthema in a patient with hairy cell leukemia treated with cladribine and allopurinol.
    Ann Hematol. 2017 Apr 8. doi: 10.1007/s00277-017-2992.
    PubMed     Text format    


  72. SHUSTIK C, Bence-Bruckler I, Delage R, Owen CJ, et al
    Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
    Ann Hematol. 2017 Apr 7. doi: 10.1007/s00277-017-2982.
    PubMed     Text format     Abstract available


  73. BRECCIA M, Pregno P, Spallarossa P, Arboscello E, et al
    Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion.
    Ann Hematol. 2017;96:549-558.
    PubMed     Text format     Abstract available


    March 2017
  74. DUNOYER-GEINDRE S, Rivier-Cordey AS, Tsopra O, Lecompte T, et al
    Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1beta.
    Ann Hematol. 2017 Mar 25. doi: 10.1007/s00277-017-2970.
    PubMed     Text format     Abstract available


  75. BOTH A, Krauter J, Damm F, Thol F, et al
    The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.
    Ann Hematol. 2017 Mar 22. doi: 10.1007/s00277-017-2967.
    PubMed     Text format     Abstract available


  76. MO XD, Zhang XH, Xu LP, Wang Y, et al
    Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2017 Mar 11. doi: 10.1007/s00277-017-2960.
    PubMed     Text format     Abstract available


  77. PAUBELLE E, Ducastelle-Lepretre S, Labussiere-Wallet H, Nicolini FE, et al
    Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
    Ann Hematol. 2017;96:363-371.
    PubMed     Text format     Abstract available


  78. HOLTICK U, Herling M, Pflug N, Chakupurakal G, et al
    Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.
    Ann Hematol. 2017;96:479-487.
    PubMed     Text format     Abstract available


  79. GORNICEC M, Wolfler A, Stanzel S, Sill H, et al
    Evidence for a role of decitabine in the treatment of myeloid sarcoma.
    Ann Hematol. 2017;96:505-506.
    PubMed     Text format    


  80. THULER LC, Pombo-de-Oliveira MS
    Acute promyelocytic leukaemia is highly frequent among acute myeloid leukaemias in Brazil: a hospital-based cancer registry study from 2001 to 2012.
    Ann Hematol. 2017;96:355-362.
    PubMed     Text format     Abstract available


    February 2017
  81. GAO N, Wang XX, Sun JR, Yu WZ, et al
    Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.
    Ann Hematol. 2017 Feb 25. doi: 10.1007/s00277-017-2948.
    PubMed     Text format     Abstract available


  82. JUD S, Goede JS, Senn O, Spanaus K, et al
    sIL2R ratio as early marker for response in hairy cell leukemia and the prognostic relevance of IL28B genotype to interferon-alpha therapy.
    Ann Hematol. 2017 Feb 18. doi: 10.1007/s00277-017-2943.
    PubMed     Text format     Abstract available


  83. ZHANG X, Pan J
    Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia.
    Ann Hematol. 2017 Feb 2. doi: 10.1007/s00277-017-2923.
    PubMed     Text format    


  84. ORIOLI L, Sarti K, Van Den Neste E, Maiter D, et al
    Transient hypophysitis in a patient treated by duvelisib for chronic lymphocytic leukemia.
    Ann Hematol. 2017 Feb 1. doi: 10.1007/s00277-017-2928.
    PubMed     Text format    


  85. ITO S, Fujiwara SI, Mashima K, Umino K, et al
    Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia.
    Ann Hematol. 2017 Feb 1. doi: 10.1007/s00277-017-2933.
    PubMed     Text format     Abstract available



  86. ACUTE LEUKEMIAS XVI.
    Ann Hematol. 2017;96.
    PubMed     Text format    


    January 2017
  87. TALAMO L, Douvas M, Macik BG, Ornan D, et al
    Successful treatment with apixaban of sinus venous thrombosis due to pegylated asparaginase in a young adult with T cell acute lymphoblastic leukemia: case report and review of management.
    Ann Hematol. 2017 Jan 28. doi: 10.1007/s00277-017-2930.
    PubMed     Text format    


  88. YOO SH, Koh Y, Kim DY, Lee JH, et al
    Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience.
    Ann Hematol. 2017 Jan 16. doi: 10.1007/s00277-017-2919.
    PubMed     Text format     Abstract available


  89. KONUMA T, Kondo T, Yamashita T, Uchida N, et al
    Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8.
    Ann Hematol. 2017 Jan 6. doi: 10.1007/s00277-016-2909.
    PubMed     Text format     Abstract available


  90. HILLER JK, Schmoor C, Gaidzik VI, Schmidt-Salzmann C, et al
    Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.
    Ann Hematol. 2017 Jan 5. doi: 10.1007/s00277-016-2912.
    PubMed     Text format     Abstract available


  91. RAM R, Gatt M, Merkel D, Helman I, et al
    Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation-a retrospective national multicenter study.
    Ann Hematol. 2017 Jan 5. doi: 10.1007/s00277-016-2914.
    PubMed     Text format     Abstract available


  92. LIU J, Qin YZ, Yang S, Wang Y, et al
    Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements.
    Ann Hematol. 2017 Jan 4. doi: 10.1007/s00277-016-2913.
    PubMed     Text format     Abstract available


  93. LEE JS, Cheong HS, Koh Y, Ahn KS, et al
    MCM7 polymorphisms associated with the AML relapse and overall survival.
    Ann Hematol. 2017;96:93-98.
    PubMed     Text format     Abstract available


  94. MANGIACAVALLI S, Pompa A, Ferretti V, Klersy C, et al
    The possible role of burden of therapy on the risk of myeloma extramedullary spread.
    Ann Hematol. 2017;96:73-80.
    PubMed     Text format     Abstract available


  95. PIREDDA ML, Catalano G, Ciardi C, Divona M, et al
    Identification of a potential topoisomerase II "hotspot" DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms.
    Ann Hematol. 2017;96:155-157.
    PubMed     Text format    


  96. FILIP AA, Grenda A, Popek S, Koczkodaj D, et al
    Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
    Ann Hematol. 2017;96:33-50.
    PubMed     Text format     Abstract available


  97. ZDRENGHEA M, Bagacean C, Renaudineau Y, Salaun PY, et al
    Isolated Cardiac Richter Syndrome: a Case Report.
    Ann Hematol. 2017;96:147-149.
    PubMed     Text format    


    December 2016
  98. GONG Z, Zheng L, Tang Z, Chen Z, et al
    Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Ann Hematol. 2016.
    PubMed     Text format    


  99. KOURIE HR, Ameye L, Paesmans M, Bron D, et al
    Re: Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis.
    Ann Hematol. 2016;95:2105-2106.
    PubMed     Text format    


  100. CATTANEO C, Zappasodi P, Mancini V, Annaloro C, et al
    Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel).
    Ann Hematol. 2016;95:1955-1963.
    PubMed     Text format     Abstract available


  101. HAERZSCHEL A, Catusse J, Hutterer E, Paunovic M, et al
    BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia.
    Ann Hematol. 2016;95:1979-1988.
    PubMed     Text format     Abstract available


    November 2016
  102. HEIBLIG M, Bidet A, Callet-Bauchu E, Dumas PY, et al
    Erratum to: BCR-ABL-positive acute myeloid leukemia: About one case treated with ponatinib.
    Ann Hematol. 2016.
    PubMed     Text format    


  103. YU CL, Zheng-Dong, Qiao ZH, Wang JM, et al
    The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative Group.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  104. YAMASAKI S, Hirakawa A, Aoki J, Uchida N, et al
    Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  105. ZHANG W, Kuang P, Li H, Wang F, et al
    Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  106. ZHENG C, Tang B, Zhu X, Zhang X, et al
    Pre-engraftment bloodstream infections in acute leukemia patients undergoing unrelated cord blood transplantation following intensified myeloablative conditioning without ATG.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  107. HIROSAWA M, Higashi T, Iwashige A, Yamaguchi T, et al
    HLA-haploidentical hematopoietic stem cell transplantation with low-dose thymoglobulin GVHD prophylaxis for an adult T cell leukemia/lymphoma patient treated with pretransplant mogamulizumab.
    Ann Hematol. 2016.
    PubMed     Text format    


  108. MAEL H, Audrey B, Evelyne CB, Pierre-Yves D, et al
    BCR-ABL-positive acute myeloid leukemia: About one case treated with ponatinib.
    Ann Hematol. 2016.
    PubMed     Text format    


  109. BRIANI C, Visentin A, Cavallaro T, Cacciavillani M, et al
    Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  110. CERVANTES F, Correa JG, Perez I, Garcia-Gutierrez V, et al
    Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  111. BOZTUG H, Muhlegger N, Potschger U, Attarbaschi A, et al
    Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  112. DIAMOND JM, de Almeida AM, Belo HJ, da Costa MP, et al
    CALR-mutated primary myelofibrosis evolving to chronic myeloid leukemia with both CALR mutation and BCR-ABL1 fusion gene.
    Ann Hematol. 2016.
    PubMed     Text format    


  113. VOGT N, Hess K, Bialek R, Buerke B, et al
    Epileptic seizures and rhinocerebral mucormycosis during blinatumomab treatment in a patient with biphenotypic acute leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  114. SCHLENK RF, Lubbert M, Benner A, Lamparter A, et al
    All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  115. DAI Z, Feng C, Zhang W, Liu J, et al
    Lack of association between cytotoxic T-lymphocyte antigen-4 gene polymorphisms and lymphoid malignancy risk: evidence from a meta-analysis.
    Ann Hematol. 2016;95:1685-94.
    PubMed     Text format     Abstract available


  116. CRISP RL, Maltaneri RE, Vittori DC, Solari L, et al
    Red blood cell aquaporin-1 expression is decreased in hereditary spherocytosis.
    Ann Hematol. 2016;95:1595-601.
    PubMed     Text format     Abstract available


  117. WU SJ, Lin CT, Lin SC, Hsieh PY, et al
    Similar epidemiological trends of pre-neoplastic precursors and their respective lymphoid malignancies in Taiwan.
    Ann Hematol. 2016;95:1727-9.
    PubMed     Text format    


  118. MLIKA M, Khanfir D, Mansouri R, El Mezni F, et al
    Multivariate analysis of prognostic factors of lymphoblastic lymphomas of the mediastinum.
    Ann Hematol. 2016;95:1731-2.
    PubMed     Text format    


  119. PARK H, Youk J, Kim I, Yoon SS, et al
    Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
    Ann Hematol. 2016;95:1777-86.
    PubMed     Text format     Abstract available


  120. CHRISTOPEIT M, Grundhoff A, Rohde H, Belmar-Campos C, et al
    Suspected encephalitis with Candida tropicalis and Fusarium detected by unbiased RNA sequencing.
    Ann Hematol. 2016;95:1919-21.
    PubMed     Text format    


    September 2016
  121. JUNCA J, Garcia O, Garcia-Caro M, Vila J, et al
    CD34 expression and the outcome of nucleophosmin 1-mutated acute myeloid leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  122. PEI YQ, Wu Y, Wang F, Cui W, et al
    Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis.
    Ann Hematol. 2016;95:1391-8.
    PubMed     Text format     Abstract available


  123. FISCHER J, Hamacher L, Fries J, Hallek M, et al
    Rhodotorula mucilaginosa as a cause of recurrent pulmonary infection and liver infiltration in a patient with CLL.
    Ann Hematol. 2016;95:1569-70.
    PubMed     Text format    


  124. BURBACH M, Birsen R, Denis B, Munier AL, et al
    A case of BK virus nephropathy without hemorrhagic cystitis after hematopoietic stem cell transplantation.
    Ann Hematol. 2016;95:1567-8.
    PubMed     Text format    


    August 2016
  125. LOW MS, Vilcassim S, Fedele P, Grigoriadis G, et al
    Acute monocytic leukemia masked by hemolytic anemia and sclerotic lesions.
    Ann Hematol. 2016.
    PubMed     Text format    


  126. REISS SN, Buie LW, Adel N, Goldman DA, et al
    Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  127. REFAEI M, Fernandes B, Brandwein J, Goodyear MD, et al
    Incidence of catheter-related thrombosis in acute leukemia patients: a comparative, retrospective study of the safety of peripherally inserted vs. centrally inserted central venous catheters.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  128. MORRISON EJ, Flynn JM, Jones J, Byrd JC, et al
    Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  129. LIU X, Liu S, Chen J, He L, et al
    Baicalein suppresses the proliferation of acute T-lymphoblastic leukemia Jurkat cells by inhibiting the Wnt/beta-catenin signaling.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  130. GOPEL W, Schnetzke U, Hochhaus A, Scholl S, et al
    Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis.
    Ann Hematol. 2016.
    PubMed     Text format    


  131. HIRABAYASHI S, Kondo T, Oka T, Akamatsu Y, et al
    Successful treatment of severe acute gastrointestinal graft-versus-host disease complicated by cytomegalovirus gastroenteritis with intra-arterial steroid infusion.
    Ann Hematol. 2016;95:1373-5.
    PubMed     Text format    


    July 2016
  132. KONISHI Y, Tada K, Nishi K, Imada K, et al
    Allogeneic bone marrow transplantation for therapy-related acute lymphocytic leukemia after autologous hematopoietic stem cell transplantation for multiple myeloma.
    Ann Hematol. 2016.
    PubMed     Text format    


  133. KIM TK, Xu ML, Podoltsev NA, Prebet T, et al
    Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  134. PETERLIN P, Garnier A, Tissot A, Garandeau C, et al
    Successful treatment of acute promyelocytic leukemia with arsenic trioxide and all-trans retinoic acid in a double lung and kidney transplanted patient.
    Ann Hematol. 2016.
    PubMed     Text format    


  135. VISWESHWAR N, Jaglal M, Booth C, Griffin P, et al
    AOHE: manuscript AOHE-D-16-00564 paroxysmal nocturnal hemoglobinuria with autoimmune hemolytic anemia following eculizumab therapy-with large granular lymphocytic leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  136. BURKHARDT B, Yavuz D, Zimmermann M, Schieferstein J, et al
    Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  137. FAYE BF, Dieng N, Seck M, Gadji M, et al
    Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  138. LIANG L, Zhao M, Zhu YC, Hu X, et al
    Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  139. NEUENDORFF NR, Burmeister T, Dorken B, Westermann J, et al
    BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  140. MOLLOY C, Cahill R, Gallagher D, Murphy P, et al
    Early-onset chronic lymphocytic leukaemia in a young man with Cowden syndrome.
    Ann Hematol. 2016;95:1205-6.
    PubMed     Text format    


  141. WU W, Lin Y, Xiang L, Dong W, et al
    Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy.
    Ann Hematol. 2016;95:1051-7.
    PubMed     Text format     Abstract available


    May 2016
  142. WU B, Ingersoll K, Rehder C, Sebastian S, et al
    Sequential development of chronic myelogenous leukemia and primary myelofibrosis in a patient with history of large B-cell lymphoma treated with radiotherapy and chemotherapy: two myeloid neoplasms with distinct genotypic profiles suggestive of biclon
    Ann Hematol. 2016.
    PubMed     Text format    


  143. BYUN JM, Kim YJ, Yoon HJ, Kim SY, et al
    Cytogenetic profiles of 2806 patients with acute myeloid leukemia-a retrospective multicenter nationwide study.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  144. BARTELS S, Lehmann U, Busche G, Schlue J, et al
    Evolution of chronic myelomonocytic leukemia to myeloproliferative neoplasm.
    Ann Hematol. 2016.
    PubMed     Text format    


  145. SEYMOUR JF
    Effective mitigation of tumor lysis syndrome with gradual venetoclax dose ramp, prophylaxis, and monitoring in patients with chronic lymphocytic leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  146. SOUTO FILHO JT, Pereira SM, Duncan LR, Alves LL, et al
    Resolution of organizing pneumonia following immunosuppressive therapy for large granular lymphocytic leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  147. CARLI G, Visco C, Falisi E, Perbellini O, et al
    Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome.
    Ann Hematol. 2016;95:863-70.
    PubMed     Text format     Abstract available


  148. ERNST J, Schafer V, Rinke J, Wittig S, et al
    Continuous molecular remission and regression of side effects after discontinuation of salvage therapy with sorafenib and donor lymphocyte infusions in a young patient with relapsed AML.
    Ann Hematol. 2016;95:1027-30.
    PubMed     Text format    


    April 2016
  149. SANZ MA, Iacoboni G, Montesinos P, Venditti A, et al
    Emerging strategies for the treatment of older patients with acute myeloid leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  150. AWAN FT, Jones JA, Maddocks K, Poi M, et al
    A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  151. GHANIZADEH-VESALI S, Zekri A, Zaker F, Zaghal A, et al
    Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  152. STAHL M, Xu ML, Steensma DP, Rampal R, et al
    Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  153. LINDNER S, Berg T, Riemann J, Ajib S, et al
    Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  154. CESARO S, Cavaliere M, Pegoraro A, Gamba P, et al
    A comprehensive approach to the prevention of central venous catheter complications: results of 10-year prospective surveillance in pediatric hematology-oncology patients.
    Ann Hematol. 2016;95:817-25.
    PubMed     Text format     Abstract available


  155. APPELMANN I, Kreher S, Parmentier S, Wolf HH, et al
    Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thromb
    Ann Hematol. 2016;95:707-18.
    PubMed     Text format     Abstract available


  156. MALAGOLA M, Papayannidis C, Baccarani M
    Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.
    Ann Hematol. 2016;95:681-93.
    PubMed     Text format     Abstract available


  157. HUANG K, Yang M, Pan Z, Heidel FH, et al
    Leukemogenic potency of the novel FLT3-N676K mutant.
    Ann Hematol. 2016;95:783-91.
    PubMed     Text format     Abstract available


    March 2016
  158. ZOELLNER AK, Hohler T, Fries S, Bohme A, et al
    Altered treatment of chronic lymphocytic leukemia in Germany during the last decade.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  159. GRATWOHL A, Iacobelli S, Bootsman N, van Biezen A, et al
    Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  160. BENETATOS L, Vartholomatos G
    On the potential role of DNMT1 in acute myeloid leukemia and myelodysplastic syndromes: not another mutated epigenetic driver.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  161. KJELLANDER C, Bjorkholm M, Kallman O, Giske CG, et al
    Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  162. MONABATI A, Safaei A, Noori S, Mokhtari M, et al
    Subtype distribution of lymphomas in South of Iran, analysis of 1085 cases based on World Health Organization classification.
    Ann Hematol. 2016;95:613-8.
    PubMed     Text format     Abstract available


  163. AHN JS, Kim HJ, Kim YK, Jung SH, et al
    Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
    Ann Hematol. 2016;95:625-35.
    PubMed     Text format     Abstract available


    February 2016
  164. URESHINO H, Miyahara M
    Spontaneous regression of adult T cell leukemia/lymphoma following development of immune thrombocytopenia.
    Ann Hematol. 2016.
    PubMed     Text format    


  165. TESTA U, Lo-Coco F
    Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  166. PICH A, Godio L, Riera L, Cavaliere C, et al
    Myelodysplastic syndrome with del (5q) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with complex karyotype.
    Ann Hematol. 2016;95:525-7.
    PubMed     Text format    


    January 2016
  167. MENON NN, Jenkins LM, Cui H, Jenkins C, et al
    Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia.
    Ann Hematol. 2016.
    PubMed     Text format     Abstract available


  168. WANG W, Ali S, Tang Z, Miranda RN, et al
    Constitutional pericentric inversion of chromosome 9 has no impact on survival in chronic myelogenous leukemia.
    Ann Hematol. 2016.
    PubMed     Text format    


  169. TANBA K, Uoshima N, Uchiyama H, Kawata E, et al
    Toxic epidermal necrolysis in adult T cell leukemia/lymphoma treated with mogamulizumab.
    Ann Hematol. 2016.
    PubMed     Text format    


  170. KUBOTA Y, Ichinohe T, Yoshimura M, Itamura H, et al
    Acute myeloid leukemia with t(3;8)(q26;q24) complicated by diabetes insipidus.
    Ann Hematol. 2016.
    PubMed     Text format    


  171. SCHNEIDAWIND D, Federmann B, Buechele C, Helwig A, et al
    Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies.
    Ann Hematol. 2016;95:115-24.
    PubMed     Text format     Abstract available


  172. HEIDENREICH D, Kreil S, Nolte F, Reinwald M, et al
    Allogeneic hematopoietic cell transplantation without fluconazole and fluoroquinolone prophylaxis.
    Ann Hematol. 2016;95:287-93.
    PubMed     Text format     Abstract available


  173. LUQUE PAZ D, Ianotto JC, Chauveau A, Guibourg B, et al
    Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.
    Ann Hematol. 2016;95:349-50.
    PubMed     Text format    


    December 2015
  174. PODHORECKA M, Macheta A, Chocholska S, Bojarska-Junak A, et al
    Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  175. LIU AP, Lee V, Li CK, Ha SY, et al
    Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide.
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  176. AHN JS, Kim JY, Kim HJ, Kim YK, et al
    Erratum to: Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
    Ann Hematol. 2015.
    PubMed     Text format    


  177. FABARIUS A, Kalmanti L, Dietz CT, Lauseker M, et al
    Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.
    Ann Hematol. 2015;94:2015-24.
    PubMed     Text format     Abstract available


  178. FASAN A, Haferlach C, Eder C, Alpermann T, et al
    Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML.
    Ann Hematol. 2015;94:1991-2001.
    PubMed     Text format     Abstract available


    November 2015
  179. LUBBERT M, Suciu S, Hagemeijer A, Ruter B, et al
    Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group
    Ann Hematol. 2015.
    PubMed     Text format     Abstract available


  180. TSCHAN-PLESSL A, Halter JP, Heim D, Medinger M, et al
    Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation.
    Ann Hematol. 2015;94:1899-905.
    PubMed     Text format     Abstract available


  181. PIEKARSKA A, Gil L, Prejzner W, Wisniewski P, et al
    Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome.
    Ann Hematol. 2015;94:1891-7.
    PubMed     Text format     Abstract available


    October 2015
  182. CHAKUPURAKAL G, Leitzke S, Langerbeins P, Schiller J, et al
    Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality--a single institution experience.
    Ann Hematol. 2015;94:1717-25.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: